8-K: Perrigo Reports Q4, FY2025 Results; $1.3B Goodwill Impairment

Perrigo announced its fourth quarter and fiscal year 2025 financial results, reporting a significant goodwill impairment while outlining strategic shifts and a new operational enhancement program.

Summary

• Fiscal Year 2025 Adjusted EPS reached $2.75, aligning with the midpoint of the updated outlook range.
• Fourth Quarter 2025 Net Sales were $1.11 billion, a 2.5% decrease year-over-year, with organic net sales declining 4.5%.
• Fourth Quarter 2025 Reported Diluted EPS was $(10.20), a significant drop from $(0.30) in the prior year, primarily due to a $1.3 billion Goodwill Impairment charge.
• Fourth Quarter 2025 Adjusted Diluted EPS was $0.77, down from $0.93.
• Fiscal Year 2025 Net Sales were $4.25 billion, a 2.8% decrease year-over-year, with organic net sales declining 2.4%.
• Fiscal Year 2025 Reported Diluted EPS was $(10.12), down from $(1.17) in the prior year, primarily due to the Goodwill Impairment charge.
• Fiscal Year 2025 Adjusted Diluted EPS was $2.75, an increase of 7.0% from $2.57.
• A new Operational Enhancement Program has been launched, expected to deliver $80 million to $100 million in pre-tax annualized savings by the end of FY2027, including a reduction of approximately 7% of the current workforce.
• The company is transitioning to new reporting segments (Self Care, Specialty Care, Infant Formula) beginning Q1 2026, aligning with its commercial operating model.
• Perrigo issued its FY2026 'All In' outlook with total net sales expected to be -5.5% to -1.5% and adjusted diluted EPS in the range of $2.00 to $2.30.
• The FY2026 'CORE' outlook, excluding Infant Formula and previously announced divestitures, projects net sales of -3.0% to +1.0% and adjusted EPS of $2.25 to $2.55, compared to FY2025 CORE adjusted EPS of $2.52.
• An agreement was signed to sell the Dermacosmetics branded business for up to €327 million, with the transaction anticipated to close in Q2 2026.
• Project Energize, an efficiency program, delivered gross annualized pre-tax savings of approximately $167 million by the end of FY2025.
• The Supply Chain Reinvention Program achieved cumulative annual run-rate benefits of $157 million in the fourth quarter of 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report, marked by a substantial goodwill impairment and declining reported earnings, despite some positive adjusted metrics and strategic initiatives. The negative outlook for FY2026 net sales and adjusted EPS suggests ongoing headwinds.

Positives

• Fiscal Year 2025 Adjusted EPS of $2.75 met the midpoint of the updated outlook range and increased 7.0% year-over-year.
• Perrigo Store Brand OTC and Key Brands gained market share in 2025 despite soft category consumption.
• The new Operational Enhancement Program is expected to deliver $80 million to $100 million in pre-tax annualized savings by the end of FY2027.
• Project Energize delivered gross annualized pre-tax savings of approximately $167 million, at the high-end of the estimated range.
• The Supply Chain Reinvention Program was successfully completed, achieving cumulative annual run-rate benefits of $157 million, within the estimated range.
• An agreement to divest the Dermacosmetics business for up to €327 million provides upfront cash and streamlines the portfolio.
• The Consumer Self-Care International (CSCI) segment showed adjusted operating income growth of 7.4% in Q4 2025 and 3.7% in FY2025.
• CSCI organic net sales grew 0.3% in FY2025.
• Operating cash flow year-to-date was $239 million, with $175 million generated in the fourth quarter.

Negatives

• Fourth Quarter 2025 Net Sales decreased 2.5% year-over-year to $1.11 billion, with organic net sales down 4.5%.
• Fiscal Year 2025 Net Sales decreased 2.8% year-over-year to $4.25 billion, with organic net sales down 2.4%.
• Fourth Quarter 2025 Reported Diluted EPS was $(10.20), a significant decline from $(0.30) in the prior year, primarily due to a $1.3 billion Goodwill Impairment charge.
• Fiscal Year 2025 Reported Diluted EPS was $(10.12), a significant decline from $(1.17) in the prior year, primarily due to the Goodwill Impairment charge.
• Fourth Quarter 2025 Adjusted EPS decreased to $0.77 from $0.93.
• Soft total OTC category consumption and a later start to cough cold seasons in the U.S. and Europe negatively impacted sales.
• The Infant Formula business unfavorably impacted Q4 organic net sales by 2.9% and FY2025 organic net sales by 0.9%.
• The Consumer Self-Care Americas (CSCA) segment experienced a 6.3% net sales decline in Q4 2025 and 4.0% in FY2025.
• There is a potential for additional noncash goodwill impairment charges of up to $350 million in Q1 2026 due to goodwill reallocation.
• The FY2026 'All In' adjusted diluted EPS outlook of $2.00 to $2.30 is lower than the FY2025 adjusted EPS of $2.75.
• The FY2026 'All In' total net sales outlook of -5.5% to -1.5% indicates continued decline.
• The operational enhancement program includes a reduction of approximately 7% of the current workforce.

Risks

• Ability to complete the proposed divestment of the Dermacosmetics branded business, including receipt of works council and regulatory approval, performance by counterparties, and the likelihood of satisfying deferred payment milestones.
• Supply chain impacts on the business, including those caused or exacerbated by armed conflict, trade and other economic sanctions, and/or disease.
• General economic, credit, and market conditions.
• Increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations.
• The impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions.
• The outbreak or escalation of conflict in other regions where business is conducted, including the Middle East.
• Current and future impairment charges, if the carrying amount of specific assets may not be recoverable from expected future cash flows.
• Customer acceptance of new products.
• Competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories.
• Pricing pressures from customers and consumers.
• Resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives.
• Uncertainty regarding the ability to obtain and maintain regulatory approvals.
• Potential costs and reputational impact of product recalls or sales halts.
• Potential adverse changes to U.S. and foreign tax, healthcare, and other government policy.
• The effect of epidemic or pandemic disease.
• The timing, amount, and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity.
• Fluctuations in currency exchange rates and interest rates.
• Receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained may exceed estimates.
• The risk that potential costs or liabilities incurred or retained in connection with the sale of the Rx business may exceed estimates or adversely affect business or operations.
• The consummation and success of other announced and unannounced acquisitions or dispositions, and the ability to realize the desired benefits thereof.
• The ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including ongoing restructuring programs.
• Adverse results with respect to pending litigation could have a material adverse impact on operating results, cash flows, and liquidity, and could ultimately require the use of corporate assets to pay damages.

Future Outlook

Perrigo projects its FY2026 'All In' net sales to decline by 1.5% to 5.5% and adjusted diluted EPS to be in the range of $2.00 to $2.30. For its 'CORE' business, which excludes Infant Formula and divested assets, net sales are expected to range from -3.0% to +1.0% and adjusted EPS from $2.25 to $2.55, compared to FY2025 CORE adjusted EPS of $2.52. The company anticipates $80 million to $100 million in annualized pre-tax savings from a new operational enhancement program by the end of FY2027, with the majority expected in FY2026.

Management Comments

• "Fiscal year 2025 was a pivotal year for Perrigo. Despite soft category consumption and a challenging Infant Formula end-market, we gained share across store brands and in key brands as our team executed with discipline." Patrick Lockwood-Taylor, President and CEO.
• "Our 'ThreeS plan' is delivering meaningful progress in stabilizing our business, streamlining our complexity and strengthening what is working, supported by cost savings program benefits and the implementation of our new commercial operating model." Patrick Lockwood-Taylor, President and CEO.
• "Looking ahead, we are prioritizing resources and investments towards CORE Perrigo, our go-forward business, which excludes the Infant Formula business under strategic review, and previously announced divestitures." Patrick Lockwood-Taylor, President and CEO.
• "Our 2026 outlook reflects near-term headwinds, balanced by favorable mix in our base business, disciplined execution of our new operational enhancement program and targeted cost actions to align our structure with current market realities." Patrick Lockwood-Taylor, President and CEO.
• "We are confident that our disciplined approach is enabling us to navigate the transition year ahead and positions Perrigo to create long-term value for our shareholders." Patrick Lockwood-Taylor, President and CEO.

Industry Context

StockSavvy.ai notes that Perrigo's performance reflects broader challenges in the consumer health sector, particularly soft OTC category consumption and specific headwinds in the infant formula market. The strategic focus on "CORE" Perrigo and divestitures aligns with a trend among consumer goods companies to streamline portfolios and focus on higher-margin, growth-oriented segments amidst economic pressures and changing consumer habits. The workforce reduction and operational enhancement program are common responses to industry-wide cost pressures and the need for increased agility.

Comparison to Industry Standards

• The reported $1.3 billion goodwill impairment charge is a significant event, indicating a re-evaluation of asset values, potentially reflecting a more conservative outlook compared to some peers who may have already taken such charges or have more stable asset valuations.
• The 7% workforce reduction is a substantial restructuring effort, comparable to similar efficiency drives seen in other large consumer goods or pharmaceutical companies facing margin pressures and seeking to optimize operational structures.
• The divestiture of the Dermacosmetics business for up to €327 million is consistent with industry trends of divesting non-core assets to focus on strategic priorities, similar to how other diversified health companies have streamlined their portfolios.
• The organic net sales decline in Q4 2025 (-4.5%) and FY2025 (-2.4%) suggests underperformance relative to some segments of the broader consumer health market, which, while facing headwinds, has seen pockets of growth in specific categories or regions.

Corporate Governance

Legal Proceedings

• Unusual litigation is mentioned as an adjustment in non-GAAP measures for both Q4 and FY2025.
• Forward-looking statements indicate risks related to the resolution of uncertain tax positions and any litigation, ongoing or future government investigations, and regulatory initiatives.
• Adverse results with respect to pending litigation could have a material adverse impact on operating results, cash flows, and liquidity.

Stakeholder Impact

• Shareholders: Significant negative impact from the $1.3 billion goodwill impairment leading to substantial reported losses. Future value creation is targeted through strategic shifts and cost savings, but the FY2026 outlook suggests continued challenges.
• Employees: Approximately 7% workforce reduction expected as part of the new operational enhancement program.
• Customers: Continued focus on store brands and key brands, with efforts to improve service levels through supply chain reinvention.
• Suppliers: Supply chain reinvention aims to strengthen resiliency, potentially impacting supplier relationships and network.
• Creditors: Total debt on the balance sheet is $3.64 billion, with a net leverage outlook of approximately 4.0 times adjusted EBITDA for FY2026, in line or slightly better than 2025.

Next Steps

• Transition to new reporting segments (Self Care, Specialty Care, Infant Formula) beginning Q1 2026.
• Potential for additional noncash goodwill impairment charges of up to $350 million in Q1 2026 due to goodwill reallocation.
• Anticipated closing of the Dermacosmetics business divestiture in Q2 2026.
• Issuance of a Form 8-K in April 2026 containing recast financial information for fiscal 2025 and 2024 under the new reporting segments.
• Execution of a two-year operational enhancement program to achieve $80 million to $100 million in pre-tax annualized savings by the end of FY2027.
• Strategic review of the Infant Formula business.

Key Dates

Recommendation

The significant $1.3 billion goodwill impairment, coupled with declining reported net sales and a lower adjusted EPS outlook for FY2026 compared to FY2025, indicates fundamental challenges and a deteriorating financial position. While strategic initiatives and cost savings are underway, the immediate future appears difficult, with potential for further impairment charges. This suggests a negative outlook for the stock.

Keywords

Perrigo, PRGO, financial results, Q4 2025, FY2025, earnings, goodwill impairment, consumer health, OTC, infant formula, divestiture, operational enhancement, cost savings, strategic review, self-care, specialty care, market share, adjusted EPS, net sales